GUANFACINE MECHANISMS, CLINICAL EFFICACY, AND ROLE IN MODERN ADHD PHARMACOTHERAPY – A REVIEW

Wiktoria Bojarska; Agnieszka Barbara Białek; Radosław Januszczak; Gabriela Anna Gilarska; Julianna Cholewa; Sylwia Bojarska; Maja Sygacz

doi:10.31435/ijitss.2(50).2026.5491

Authors

Wiktoria Bojarska University Clinical Hospital No. 4 in Lublin, ul. Doktora Kazimierza Jaczewskiego 8, 20-090 Lublin, Poland https://orcid.org/0009-0008-6923-2068
Agnieszka Barbara Białek Medical University of Lublin, Faculty of Medicine, ul. Witolda Chodźki 19, 20-093 Lublin, Poland https://orcid.org/0009-0004-0855-7732
Radosław Januszczak University Clinical Hospital No. 4 in Lublin, ul. Doktora Kazimierza Jaczewskiego 8, 20-090 Lublin, Poland https://orcid.org/0009-0007-4088-8138
Gabriela Anna Gilarska Medical University of Lublin, Faculty of Medicine, ul. Witolda Chodźki 19, 20-093 Lublin, Poland https://orcid.org/0009-0004-4818-8070
Julianna Cholewa Human Anatomy Research Group, Medical University of Lublin, Jaczewskiego 4, 20-400, Lublin, Poland https://orcid.org/0009-0007-2432-1828
Sylwia Bojarska Cognitive Institute - Cognitive-Behavioural Psychotherapy School, ul. Bonerowska 2/5, 31-030 Kraków, Poland https://orcid.org/0009-0006-1277-8452
Maja Sygacz University Clinical Hospital No. 4 in Lublin, ul. Doktora Kazimierza Jaczewskiego 8, 20-090 Lublin, Poland https://orcid.org/0009-0006-8689-8975

DOI:

https://doi.org/10.31435/ijitss.2(50).2026.5491

Keywords:

ADHD, Guanfacine, Alpha-2A Adrenergic Receptor, Non-Stimulant Treatment, ADHD Pharmacotherapy

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder worldwide. It affects cognitive, behavioural, and social functioning across the lifespan. Symptoms such as inattention, hyperactivity, and impulsivity can significantly impair academic, occupational, and interpersonal outcomes. Stimulant medications, including methylphenidate and amphetamine derivatives, remain the first-line treatment due to their robust efficacy. However, their use is often limited by side effects, risk of misuse, and incomplete response in a substantial subset of patients. These limitations have driven growing interest in non-stimulant pharmacotherapies that target alternative neurobiological mechanisms.

Guanfacine, a selective alpha-2A adrenergic receptor agonist, has emerged as a promising non-stimulant option. By enhancing prefrontal cortex signalling through alpha-2A receptor agonism, guanfacine stabilises neuronal firing, which improves working memory, attention regulation, and inhibitory control. Clinical studies indicate that guanfacine is particularly effective in reducing hyperactivity and impulsivity and can serve as an adjunctive therapy in patients with partial stimulant response. Its sedative effects may also provide additional benefits for comorbid sleep disturbances and anxiety, while its non-stimulant profile lowers the risk of abuse.

Common adverse effects include sedation, hypotension, and bradycardia, necessitating careful dose titration and monitoring. Evidence regarding long-term efficacy and safety, particularly in adults, remains limited, emphasising the need for further research to optimise individualised treatment strategies. Nonetheless, guanfacine represents an important addition to ADHD pharmacotherapy, offering clinicians a valuable tool to tailor interventions according to patient-specific symptom profiles and treatment goals.

References

Ostinelli, E. G., Schulze, M., Zangani, C., Farhat, L. C., Tomlinson, A., Del Giovane, C., Chamberlain, S. R., Philipsen, A., Young, S., Cowen, P. J., Bilbow, A., Cipriani, A., & Cortese, S. (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: A systematic review and component network meta-analysis. The Lancet Psychiatry, 12(1), 32–43. https://doi.org/10.1016/S2215-0366(24)00360-2

Noah, A. A., & Sedky, H. E. (2025). New frontiers in pharmacological treatment of attention-deficit hyperactivity disorder. Naunyn-Schmiedeberg’s Archives of Pharmacology, 398(11), 15025–15035. https://doi.org/10.1007/s00210-025-04328-z

Taipale, H., Bergström, J., Gèmes, K., Tanskanen, A., Ekselius, L., Mittendorfer-Rutz, E., & Helgesson, M. (2024). Attention-deficit/hyperactivity disorder medications and work disability and mental health outcomes. JAMA Network Open, 7(3), Article e242859. https://doi.org/10.1001/jamanetworkopen.2024.2859

Kawasaki, Y., Suzuki, Y., Miyazaki, K., Suzuki, N., Hoshina, M., Kato, A., Morita, H., & Go, H. (2026). A retrospective single-center study on the characteristics of children with attention-deficit hyperactivity disorder requiring early drug therapy from 2013 to 2022 and changes in treatment over time. Fukushima Journal of Medical Science, 72(1), 31–40. https://doi.org/10.5387/fms.25-00016

Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022). Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacology & Therapeutics, 230, Article 107940.

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Association Publishing.

Petrovic, P., & Castellanos, F. X. (2016). Top-down dysregulation—from ADHD to emotional instability. Frontiers in Behavioral Neuroscience, 10, Article 70. https://doi.org/10.3389/fnbeh.2016.00070

Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., Rohde, L. A., Sonuga-Barke, E. J., Tannock, R., & Franke, B. (2015). Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers, 1, Article 15020. https://doi.org/10.1038/nrdp.2015.20

Craddock, E. (2026). Navigating residual diagnostic categories: The lived experiences of women diagnosed with autism and ADHD in adulthood. Health, 30(2), 235–257. https://doi.org/10.1177/13634593251336163

Association of the Scientific Medical Societies in Germany. (2024). German S3 guideline “ADHD in children, adolescents and adults” [Langfassung der interdisziplinären evidenz-und konsensbasierten (S3) Leitlinie “Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend-und Erwachsenenalter”-AWMF-Registernummer 028-045].

Doi, K., Sogawa, R., Eguchi, Y., Matsuo, M., & Shimanoe, C. (2024). Association between early guanfacine discontinuation and somnolence for attention-deficit/hyperactivity disorder. Biological & Pharmaceutical Bulletin, 47(6), 1204–1208. https://doi.org/10.1248/bpb.b24-00147

de Cássia Collaço, R., Lammens, M., Blevins, C., Rodgers, K., Gurau, A., Yamauchi, S., Kim, C., Forrester, J., Liu, E., Ha, J., Mei, Y., Boehm, C., Wohler, E., Sobreira, N., Rowe, P. C., Valle, D., Brock, M. V., & Bosmans, F. (2024). Anxiety and dysautonomia symptoms in patients with a NaV1.7 mutation and the potential benefits of low-dose short-acting guanfacine. Clinical Autonomic Research, 34(1), 191–201. https://doi.org/10.1007/s10286-023-01004-1

Michelini, G., Lenartowicz, A., Diaz-Fong, J. P., Bilder, R. M., McGough, J. J., McCracken, J. T., & Loo, S. K. (2023). Methylphenidate, guanfacine, and combined treatment effects on electroencephalography correlates of spatial working memory in attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 62(1), 37–47. https://doi.org/10.1016/j.jaac.2022.06.017

Inoue, F., Okazaki, Y., Kashiwa, K., Ichiba, T., & Namera, A. (2024). QT-interval prolongation associated with supratherapeutic guanfacine concentration: A case report. Journal of Medical Toxicology, 20(2), 218–221. https://doi.org/10.1007/s13181-023-00986-8

Michelini, G., Lenartowicz, A., Vera, J. D., Bilder, R. M., McGough, J. J., McCracken, J. T., & Loo, S. K. (2023). Electrophysiological and clinical predictors of methylphenidate, guanfacine, and combined treatment outcomes in children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 62(4), 415–426. https://doi.org/10.1016/j.jaac.2022.08.001

Torun, I. M., Vatansever Pinar, Z., & İlhan, Ş. (2025). The effect of guanfacine treatment on ocular parameters in pediatric and adolescents patients with attention-deficit/hyperactivity disorder. BMC Ophthalmology, 25(1), Article 56. https://doi.org/10.1186/s12886-025-03886-3

Miyazaki, K., & Uchiyama, M. (2023). An adolescent boy with kleptomania and attention-deficit hyperactivity disorder treated with methylphenidate and guanfacine: A case report. Neuropsychopharmacology Reports, 43(4), 650–653. https://doi.org/10.1002/npr2.12394

Rocha, N. S., Correa, R. D. E. S. A., Dias, A. C. M., & Bueno, C. D. F. (2023). Association between sleep pattern and pharmacological treatment in children with attention deficit disorder with hyperactivity: A systematic review. Revista Paulista de Pediatria, 41, Article e2022065. https://doi.org/10.1590/1984-0462/2023/41/2022065

Baweja, R., Baweja, R., Weidlich, H., Nyland, J. E., Waschbusch, D. A., & Waxmonsky, J. G. (2024). Treatment utilization pattern of preschool children with attention-deficit/hyperactivity disorder. Journal of Attention Disorders, 28(5), 708–721. https://doi.org/10.1177/10870547231215287

Voetterl, H., van Wingen, G., Michelini, G., Griffiths, K. R., Gordon, E., DeBeus, R., Korgaonkar, M. S., Loo, S. K., Palmer, D., Breteler, R., Denys, D., Arnold, L. E., du Jour, P., van Ruth, R., Jansen, J., van Dijk, H., & Arns, M. (2023). Brainmarker-I differentially predicts remission to various attention-deficit/hyperactivity disorder treatments: A discovery, transfer, and blinded validation study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 8(1), 52–60. https://doi.org/10.1016/j.bpsc.2022.02.007

Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022). Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacology & Therapeutics, 230, Article 107940. https://doi.org/10.1016/j.pharmthera.2021.107940

Takahashi, Y., Mikami, K., Kimoto, K., Onishi, Y., Yamamoto, K., & Matsumoto, H. (2022). A case of nocturnal enuresis associated with attention-deficit/hyperactivity disorder successfully treated with guanfacine monotherapy. The Tokai Journal of Experimental and Clinical Medicine, 47(2), 72–74.

Wagener, N., Lehmann, W., Weiser, L., Jäckle, K., Di Fazio, P., Schilling, A. F., & Böker, K. O. (2022). Psychostimulants modafinil, atomoxetine and guanfacine impair bone cell differentiation and MSC migration. International Journal of Molecular Sciences, 23(18), Article 10257. https://doi.org/10.3390/ijms231810257

Galvez-Contreras, A. Y., Vargas-de la Cruz, I., Beltran-Navarro, B., Gonzalez-Castaneda, R. E., & Gonzalez-Perez, O. (2022). Therapeutic approaches for ADHD by developmental stage and clinical presentation. International Journal of Environmental Research and Public Health, 19(19), Article 12880. https://doi.org/10.3390/ijerph191912880

Pan, P. Y., Jonsson, U., Şahpazoğlu Çakmak, S. S., Häge, A., Hohmann, S., Nobel Norrman, H., Buitelaar, J. K., Banaschewski, T., Cortese, S., Coghill, D., & Bölte, S. (2022). Headache in ADHD as comorbidity and a side effect of medications: A systematic review and meta-analysis. Psychological Medicine, 52(1), 14–25. https://doi.org/10.1017/S0033291721004141

Law, R., Lewis, D., Hain, D., Daut, R., DelBello, M. P., Frazier, J. A., Newcorn, J. H., Nurmi, E., Cogan, E. S., Wagner, S., Johnson, H., & Lanchbury, J. (2022). Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using in vitro models of hepatic metabolism. Xenobiotica, 52(7), 676–686. https://doi.org/10.1080/00498254.2022.2141151

Kawabe, K., Horiuchi, F., Matsumoto, Y., Inoue, S., Okazawa, M., Hosokawa, R., Nakachi, K., Soga, J., & Ueno, S. I. (2024). Practical clinical guidelines and pharmacological treatment for attention-deficit hyperactivity disorder in Asia. Neuropsychopharmacology Reports, 44(1), 29–33. https://doi.org/10.1002/npr2.12381